This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2002 Dec;4(6):497.

doi: 10.1007/s11926-002-0055-4.

Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor-alpha

Christopher T Ritchlin¹

Affiliations

Affiliation

¹ Allergy/Immunology and Rheumatology Unit, Strong Memorial Hospital/University of Rochester Medical Center, Box 695, 601 Elmwood Avenue, Rochester, NY 14642, USA. christopher_ritchlin@urmc.rochester.edu

PMID: 12427363
DOI: 10.1007/s11926-002-0055-4

Comment

Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor-alpha

Christopher T Ritchlin. Curr Rheumatol Rep. 2002 Dec.

. 2002 Dec;4(6):497.

doi: 10.1007/s11926-002-0055-4.

Author

Christopher T Ritchlin¹

Affiliation

¹ Allergy/Immunology and Rheumatology Unit, Strong Memorial Hospital/University of Rochester Medical Center, Box 695, 601 Elmwood Avenue, Rochester, NY 14642, USA. christopher_ritchlin@urmc.rochester.edu

PMID: 12427363
DOI: 10.1007/s11926-002-0055-4

No abstract available

PubMed Disclaimer

Comment on

Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.
Gorman JD, Sack KE, Davis JC Jr. Gorman JD, et al. N Engl J Med. 2002 May 2;346(18):1349-56. doi: 10.1056/NEJMoa012664. N Engl J Med. 2002. PMID: 11986408 Clinical Trial.

Publication types

Actions

LinkOut - more resources

Research Materials
- NCI CPTC Antibody Characterization Program